30 closest matches · ranked by relevance
Pouchitis
Primary: Percentage of Participants With Chronic or Recurrent Pouchitis Achieving Clinically Relevant Remission at Week 14 — 9.8; 31.4 percentage of participants — p=0.013
Pouchitis
Primary: Proportion of Patients With Endoscopic Remission — 3; 3 Participants
Pouchitis · Ulcerative Colitis
Primary: Clinical Remission — 4; 5 Participants — p=0.183
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Ulcerative Colitis
Primary: Proportion of Subjects With Remission — 19; 13 Participants — p=>0.05
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Sclerosing Cholangitis
Primary: Adverse Event Frequency — 8 Participants
Ulcerative Colitis
Primary: Proportion of Subjects With Remission at Month 6 — 82; 67 Participants — p=>0.05
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants
Clostridium Difficile Infection · Infection · Communicable Diseases
Primary: Safety and Tolerability of RBX2660 in Subjects With Recurrent CDI. — 697 Participants
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Clostridium Difficile Infection (CDI)
Primary: Efficacy of RBX2660 Compared to Placebo Through 8 Weeks — 57.5; 70.6 Model-estimated percent of participants
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
Ulcerative Colitis
Primary: Fecal Calprotectin Level <50µg/g — 7; 1 participants
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Ulcerative Colitis
Primary: Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories — 9.1; 3.4; 10.5; 13.0 Percentage of participants
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 38.3; 25.8 percentage of participants — p=0.0324
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Proctitis · Proctosigmoiditis
Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001
Crohn's Disease
Primary: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year — 1; 11 participants — p=.0005
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Irritable Bowel Syndrome
Primary: Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period — -4; -13 score on a scale
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213